-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 22, Pfizer announced that the National Medical Products Administration of China has approved Bebossa® (Ogaituzumab for injection) for relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R /R B-ALL) adult patients, this is also the world's first approved antibody-drug conjugate (ADC) for the treatment of R/R B-ALL
Leukemia is a common tumor of the blood and lymphatic system.
ADC drugs have changed the treatment status of adult R/R ALL patients
Note: The original text has been deleted
Reference materials:
1.
2.
3.
4.
5.
6.
7.